Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Corbus Pharmaceuticals ( (CRBP) ).
On March 9, 2026, Corbus Pharmaceuticals reported fourth-quarter and full-year 2025 results, highlighting strong clinical progress across its pipeline and a bolstered balance sheet. In oncology, Q4 2025 Phase 1/2 data for CRB-701 in head and neck squamous cell carcinoma, cervical cancer and bladder cancer showed encouraging unconfirmed response rates and favorable safety, with 2026 catalysts including FDA feedback on registrational study designs, mid-2026 monotherapy durability data, and late-2026 Keytruda combination data in first-line HNSCC.
In obesity, Corbus reported December 2025 Phase 1a SAD/MAD data for CRB-913 showing a 2.9% placebo-adjusted 14-day weight loss with a favorable gastrointestinal and neuropsychiatric profile, and it expects to complete a 12-week, 240-patient Phase 1b study in summer 2026. The company also completed a Phase 1 trial of CRB-601 but has deprioritized the program, and despite a wider quarterly net loss driven by higher clinical spending, a $75 million Q4 2025 equity offering lifted cash and investments to $163.3 million at year-end, extending the operating runway into 2028 and reinforcing Corbus’s ability to advance its lead assets in a competitive oncology and obesity landscape.
The most recent analyst rating on (CRBP) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
Spark’s Take on CRBP Stock
According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.
The score is held back primarily by weak financial performance (no revenue, sizable losses and cash burn) and bearish technical signals (below major moving averages with negative MACD). Offsetting factors include a low-debt balance sheet and positive recent corporate events around pipeline progress and financing that may improve operating runway into upcoming clinical milestones.
To see Spark’s full report on CRBP stock, click here.
More about Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies in oncology and obesity, with a pipeline led by CRB-701, a next-generation Nectin-4-targeting antibody-drug conjugate for solid tumors, and CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. Headquartered in Norwood, Mass., the company focuses on leveraging well-understood biological pathways to address serious illnesses in cancer and metabolic disease.
Average Trading Volume: 275,953
Technical Sentiment Signal: Sell
Current Market Cap: $140.6M
Learn more about CRBP stock on TipRanks’ Stock Analysis page.